No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SNDX240517C20000
- 1.67
- 0.000.00%
15min DelayTrading May 10 11:53 ET
0.00High0.00Low
0.00Open1.67Pre Close0 Volume36 Open Interest20.00Strike Price0.00Turnover41.70%IV0.31%PremiumMay 17, 2024Expiry Date1.11Intrinsic Value100Multiplier4DDays to Expiry0.56Time Value100Contract SizeAmericanOptions Type0.8739Delta0.2131Gamma17.97Leverage Ratio-0.0246Theta0.0021Rho15.70Eff Leverage0.0048Vega
Intraday
- 5D
- 1D
News
Syndax Pharmaceuticals (SNDX) Gets a Buy From Stifel Nicolaus
Express News | Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Express News | Syndax Pharmaceuticals Inc : Stifel Raises Target Price to $40 From $39
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Express News | HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Comments
$Syndax Pharmaceuticals(SNDX.US$ Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...
Syndax Pharmaceuticals' excess liquidity indicates a cautious approach to debt, but its lack of significant operating revenue and EBIT loss over the last year are worrying. The company's balance sheet appears liquid, but the absence of regular free cash flow generation is concerning.
$Syndax Pharmaceuticals(SNDX.US$ Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
$Syndax Pharmaceuticals(SNDX.US$ See a lot of potential here? with price action after trial PR, its like everyone read ( trial stopped early ) but didn’t read any further? it was stopped for efficacy, it showed improvement and are moving on to next phase!
Read more